Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,602.50
Bid: 1,602.00
Ask: 1,603.00
Change: -164.00 (-9.28%)
Spread: 1.00 (0.062%)
Open: 1,616.50
High: 1,620.00
Low: 1,589.50
Prev. Close: 1,766.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks End Up As Fed and BoJ Decisions Loom

Wed, 27th Apr 2016 15:56

LONDON (Alliance News) - UK shares ended higher Wednesday, with focus on the US Federal Reserve interest rate decision due later today, while investors will have to keep on their toes for the same by the Bank of Japan in the early hours of Thursday.

The FTSE 100 ended up 0.6%, or 35.39 points, at 6,319.91. The FTSE 250 ended up 0.8%, or 138.22 points, at 17,083.71, and the AIM-All Share fell 0.14 points to 729.08.

The Fed monetary policy decision is scheduled for 1900 BST. Economists overwhelmingly expect the central bank to leave its Federal Funds rate target unchanged, but a calmer global macroeconomic backdrop could mean the Fed hints at a rate rise at its next meeting in June.

FOREX.com analyst Fawad Razaqzada also expects the Fed not to announce changes to its monetary policy. However, Razaqzada said investors will scan the statement searching for clues on whether the Fed will hike rates in its next meeting.

"The dollar and other financial markets could...move sharply depending on the language the Federal Open Market Committee uses in the policy statement to describe the health of the world's largest economy, inflation outlook and the likely path of future interest rate changes," Razaqzada said. "This will have indirect impact on some commodities which are priced in the US dollar, such as gold and silver."

Brent oil touched a high of USD47.02 a barrel Wednesday, a level it hasn't seen since mid-November. The North Sea benchmark was adding to its Tuesday gains, when crude prices increased after the American Petroleum Institute reported a draw of nearly 1.1 million barrels in US oil inventories last week.

However, oil prices then retreated Wednesday after the US Energy Information Administration reported a 2 million-barrel climb in crude-oil supplies for the week ended April 22.

Brent was standing at USD46.12 a barrel at the London equities close, higher than the USD45.60 at the same time Tuesday. Meanwhile, gold was quoted at USD1,247.60 an ounce at the close, compared to the USD1,241.76 an ounce on Tuesday.

Stocks in New York were lower at the London equities close, with the Dow 30 down 0.1% and the S&P 500 down 0.2%.

The Nasdaq Composite was down 0.8%, hit by technology giant Apple's drop in profit in the second-quarter, hurt largely by a double-digit revenue decline that reflected weak iPhone sales. Apple reported its results Tuesday after the Wall Street close. Apple shares were down 5.6% at the London close.

In addition to the Fed this week is a Bank of Japan policy decision set for Thursday at 0400 BST. The Japanese central bank will conclude its two-day policy meeting, with analysts widely expecting it to announce a slew of measures to help weaken the yen.

"Given past policy behaviour, we therefore expect the BoJ's chairman Kuroda to be ready to surprise the markets again this year," said Maitland analyst Cebuan Bliss. "'Helicopter money', a consumption subsidy rather of fiscal policy nature, could become a frantic option, as Prime Minister Abe's reform policies have disappointed so far."

Helicopter money refers to a radical form of monetary policy that involves printing large sums of money and distributing it to the public in order to stimulate the economy, like a helicopter scattering euro notes to a crowd.

The UK economy grew at a slower pace, as expected, in the first quarter, preliminary estimates from the Office for National Statistics showed. Gross domestic product grew 0.4%, from a quarter ago, when it expanded 0.6%. This was in line with expectations.

Output increased in the dominant services sector by 0.6%. The other three main industrial groupings within the economy decreased, with production falling by 0.4%, construction output by 0.9% and agriculture by 0.1%.

On a yearly basis, UK GDP grew 2.1% in the first quarter, slightly faster than the expected growth of 2.0%.

Another report from the ONS showed the UK index of services rose 2.5% in February from last year, with the largest contribution coming from distribution, hotels and restaurants and business services and finance. Month-on-month, services output edged up 0.1%, the same pace of growth as in January.

The pound gyrated heavily before and after the economic data, with sterling reaching an intraday high of USD1.4621 prior and then declining to a low of USD1.4550 shortly afterwards. The pound stood at USD1.4544 at the London close compared to USD1.4590 at the close Tuesday.

The euro was quoted at USD1.1308 at the close, slightly lower than USD1.1310 on Tuesday.

In Paris, the CAC 40 index ended up 0.6%, and the DAX 30 in Frankfurt rose 0.4%.

On the London Stock Exchange, Worldpay Group ended up 4.3%, benefiting from an upgrade by UBS to Buy from Neutral. The Swiss bank said Worldpay's exposure to online transactions and significant investment in new value-added services will enable the company to outgrow its peers.

GlaxoSmithKline ended up 2.0% after the drugmaker pleased investors as it clarified its 2016 earnings guidance after an "encouraging" start to the year, implying higher earnings growth than previously indicated, as it continued to see benefits from its three part deal with Novartis AG in 2014.

GlaxoSmithKline's first quarter results beat expectations, helped by strong growth from its vaccines and consumer healthcare businesses, bolstered by the acquisitions it made from Novartis, which offset a small decline to its pharmaceuticals segment following the sale of its oncology business to the Swiss pharmaceutical firm.

Barclays ended up 0.5%, after an intense day for the stock following the lender's first-quarter earnings. The bank said the results showed a core business in rude health even as the bank saw a 25% drop in pretax profit. The stock opened higher, reaching 182.00 pence, its highest level since early-February. However, the shares declined since, closing at 174.80p.

Pretax profit fell to GBP793 million in the three months ended March 31, Barclays said, down from GBP1.06 billion the corresponding quarter a year earlier, with income net of insurance claims down 11% to GBP5.04 billion and credit impairment charges up 15% to GBP443 million. The results were ahead of analyst expectations, reflecting a strong performance in the bank's core business and resilience in its investment banking business.

Emerging-market-focused peer Standard Chartered fell 1.1%, among the worst blue-chip performers, having been downgraded to Sell from Hold by Deutsche Bank. The stock gave back only part of the gains it made Tuesday, when it added 9.8%, reaching its highest level in 2016, after its first-quarter loan impairment charges and capital strength proved better than the market had expected.

In the FTSE 250, Amec Foster Wheeler rose 3.7%, ending among the best performers. The oilfield services company said it has appointed Jonathan Lewis, who has held several senior roles at US giant Halliburton, as its new chief executive, as the company reported a drop in revenue in the first quarter of 2016.

Revenue in the quarter amounted to GBP1.30 billion, 1.5% lower than the GBP1.32 billion booked a year earlier. Revenue was also down 3.1% on a like-for-like basis compared to the previous year. The company's order book stood at GBP6.40 billion at the end of March, compared to GBP6.60 billion at the end of 2015, representing a 3.0% fall.

Societe Generale held a Buy recommendation on the company as the French bank believes this was "a 'normal' but relatively resilient performance in the current environment".

At the other end of the index, McCarthy & Stone dropped 6.1% after funds managed by Anchorage Capital, TPG Special Situations Partners, Goldman Sachs European Special Situations Group and Strategic Value Partners sold 85.0 million shares in the retirement housebuilder, increased from the 75.0 million they had initially planned to sell.

The gross proceeds from the sale to the selling investors were around GBP200.0 million. Following the sale, Anchorage holds a 7.6% stake, TPG a 3.9% stake, Goldman Sachs a 3.9% stake and Strategic Value Partners a 4.2% stake.

In the UK corporate calendar Thursday, Lloyds Banking Group, Taylor Wimpey, WPP, Schroders, Aggreko, Howden Joinery Group, Tullow Oil, Weir Group, Kaz Minerals, Berendsen, NCC Group and Synthomer issue trading statements. Air Partner, Oxford Biomedica, Harvey Nash Group, Camelia, GameAccount Network, U and I Group and Petropavlovsk release full-year results. Avocet Mining publishes a first-quarter production statement.

In the economic calendar, Japan's housing starts data are due at 0600 BST. The UK's nationwide housing prices are due at 0700 BST, while the eurozone's consumer confidence data are at 1000 BST. Germany's consumer price index is due at 1300 BST.

In the US, initial and continuing jobless claims and gross domestic product data are both due at 1330 BST, while the Energy Information Association natural gas storage data are due at 1530 BST.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 12:10

LONDON MARKET MIDDAY: Stocks down before Fed minutes and US PMI data

(Alliance News) - Stock prices in London were down at midday on Wednesday, in cautious trade ahead of key US data and central bank minutes in the afternoon.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
29 Dec 2023 13:01

LONDON MARKET CLOSE: UK equities outclassed by other markets in 2023

(Alliance News) - Stock prices in London closed mixed on Friday, the final trading day of 2023, as the annual returns from UK equities were outshone by international markets.

Read more
20 Dec 2023 13:29

GSK buys rights to Hansoh Pharma antibody-drug conjugate

(Sharecast News) - GSK has agreed to buy the rights to an antibody-drug conjugate (ADC) - HS-20093 - from Chinese biopharmaceutical group Hansoh Pharma.

Read more
19 Dec 2023 15:36

German court quashes CureVac patent after challenge by BioNTech

CureVac shares drop 40%Dispute over intellectual property with BioNTech to continue

*

Read more
18 Dec 2023 17:21

Energy stocks lift UK's FTSE 100, Vodafone shines

Vodafone jumps as Iliad offers to merge Italian units

*

Read more
18 Dec 2023 10:07

GSK's dostarlimab trial in endometrial cancer meets primary endpoint

(Alliance News) - GSK PLC on Monday said a trial of dostarlimab in combination with niraparib for treating endometrial cancer has met its primary endpoint.

Read more
18 Dec 2023 07:55

LONDON BRIEFING: Games Workshop seals Amazon deal for Warhammer 40,000

(Alliance News) - Stocks in London were set to retreat slightly on Monday, in line with equity markets in Asia, at the start of the last week before the Christmas holidays.

Read more
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.